[Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].

Abstract

Immuno-chemotherapeutic effects on the growth of MM-48 mammary tumor were studied in syngeneic C3H/He mice fed diets containing a low (D), normal (N) or arginine-supplemented (NA) protein content. The serum protein levels were 5.7 g/dl in N-mice and 3.7 g/dl in D-mice, respectively. On the other hand, no difference was seen between the two groups, with regard to intra-tumoral protein concentrations. The natural killer (NK) activity of spleen cells was significantly lower in D-mice than in N-or NA-mice. Augmentation of NK activity was detected following the i.p. injection of OK-432 or LENTINAN, while no augmentation was recognized in D-mice. Interferon production of cultured spleen cells was significantly reduced in D-mice, and significantly increased in NA-mice compared with N-mice. NK activity was markedly augmented at 7 days after bilateral oophorectomy in N-mice. Both NK and IFN titers were significantly reduced following administration of estradiol every 7 days. The growth of MM-48 tumor was inhibited by daily administration of OK-432 or LENTINAN in N-mice. However, the tumor growth was paradoxically accelerated after administration of the same drugs in D-mice. These findings indicated that the nutritional or endocrine environment of cancer-bearing mice plays an important role in the effect of some kinds of BRMs. A clinical randomized study of advanced and recurrent gastric cancer patients treated with MMC and FT (MF) with or without LENTINAN, was then performed. We recognized excellent end-point results only in LENTINAN-administered patients with normal protein levels, while no effect of LENTINAN was seen in patients with low protein levels (below 6.0 g/dl).

• Authors: M Akimoto, T Nishihira, M Kasai
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 4 Pt 2 Pg. 1270-6 (Apr 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3729450 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Lentinan
• Picibanil
• Fluorouracil

Topics

• Animals
• Combined Modality Therapy
• Endocrine Glands (physiology)
• Female
• Fluorouracil (therapeutic use)
• Humans
• Lentinan (therapeutic use)
• Mammary Neoplasms, Experimental (therapy)
• Mice
• Mice, Inbred C3H
• Neoplasms (immunology, therapy)
• Neoplasms, Experimental (therapy)
• Nutritional Physiological Phenomena
• Picibanil (therapeutic use)
• Stomach Neoplasms (therapy)